Trials / Unknown
UnknownNCT01680523
Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)
A Randomized Controlled Trial Comparing Radical Hysterectomy Plus Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 409 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- Female
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare 5-year overall survival between patients who undergo radical hysterectomy followed by tailored adjuvant therapy and patients who receive primary chemoradiation therapy in FIGO stage IB2 and IIA2 cervical cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Radical hysterectomy | Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed |
| RADIATION | Tailored adjuvant therapy | After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed. |
| RADIATION | Primary chemoradiation therapy | Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy. |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2012-09-07
- Last updated
- 2017-05-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01680523. Inclusion in this directory is not an endorsement.